Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors are vital in cancer immunotherapy.
• Current monoclonal antibody therapies show efficacy but are limited by immune-related adverse reactions (irAEs).

Purpose of the Study:

• To review the mechanism of action of PD-1/PD-L1 inhibitors.
• To present clinical trials and adverse reactions of approved PD-1/PD-L1 drugs.
• To highlight novel small molecule, peptide, and macrocycle inhibitors targeting the PD-1/PD-L1 axis.

Main Methods:

• Literature review of PD-1/PD-L1 inhibitors.
• Analysis of clinical trial data for approved PD-1/PD-L1 therapies.
• Survey of recently patented novel PD-1/PD-L1 inhibitors.

Main Results:

• PD-1/PD-L1 inhibitors offer significant therapeutic benefits across various cancers.
• Serious irAEs associated with PD-1/PD-L1 monoclonal antibodies necessitate careful clinical management.
• Emerging small molecules, peptides, and macrocycles present promising alternatives with potential for improved safety profiles.

Conclusions:

• There is an urgent need for novel PD-1/PD-L1 inhibitors to overcome the limitations of current antibody-based treatments.
• Understanding irAEs is critical for optimizing clinical application and management strategies.
• Newly patented inhibitors offer promising avenues for future cancer immunotherapy development.